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Abstract
Objective Treatment options for non-hospitalised
patients with coronavirus disease 2019 (COVID-19) to
reduce morbidity, mortality and spread of the disease are
an urgent global need. The over-the-counter histamine-2
receptor antagonist famotidine is a putative therapy
for COVID-19. We quantitively assessed longitudinal
changes in patient reported outcome measures in
non-hospitalised patients with COVID-19 who self-
administered high-dose famotidine orally.
Design Patients were enrolled consecutively after
signing written informed consent. Data on demographics,
COVID-19 diagnosis, famotidine use, drug-related side
effects, temperature measurements, oxygen saturations
and symptom scores were obtained using questionnaires
and telephone interviews. Based on a National Institute
of Health (NIH)-endorsed Protocol to research Patient
Experience of COVID-19, we collected longitudinal
severity scores of five symptoms (cough, shortness of
breath, fatigue, headaches and anosmia) and general
unwellness on a four-point ordinal scale modelled on
performance status scoring. All data are reported at
the patient level. Longitudinal combined normalised
symptom scores were statistically compared.
Results Ten consecutive patients with COVID-19
who self-administered high-dose oral famotidine were
identified. The most frequently used famotidine regimen
was 80 mg three times daily (n=6) for a median of
11 days (range: 5–21 days). Famotidine was well
tolerated. All patients reported marked improvements of
disease related symptoms after starting famotidine. The
combined symptom score improved significantly within
24 hours of starting famotidine and peripheral oxygen
saturation (n=2) and device recorded activity (n=1)
increased.
Conclusions The results of this case series suggest
that high-dose oral famotidine is well tolerated and
associated with improved patient-reported outcomes in
non-hospitalised patients with COVID-19.

Introduction

Management of patients with coronavirus disease
2019 (COVID-19), caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2),
poses a major challenge to the biomedical
community, governments and global population.
Currently, most research focuses on vaccine development or pharmacological treatment strategies for

Significance of this study
What is already known on this subject?

►► COVID-19 is a global pandemic caused by the

severe acute respiratory syndrome coronavirus
2. COVID-19 is highly contagious and causes a
spectrum of disorders ranging from relatively
mild symptoms to life-threatening conditions.
Medical therapies that interrupt COVID-19
progression in non-hospitalised symptomatic
patients are therefore highly sought.

What are the new findings?

►► We devised a method to quantitatively follow

six common symptoms in non-hospitalised
patients with COVID-19 over the course of
their illness. The individually normalised patient
symptoms revealed that the self-administration
of the histamine-2 receptor antagonist
famotidine is associated with symptomatic
improvements in a case series of 10 consecutive
patients.

How might it impact on clinical practice in the
foreseeable future?
►► Our findings support the rigorous evaluation
of famotidine as a potential therapy and of the
use of symptom tracking for non-hospitalised
patients with COVID-19.

hospitalised patients with COVID-19.1 However,
to reduce global morbidity and mortality, effective
treatment strategies for non-
hospitalised patients
are required.
Famotidine may be a candidate medication for
this. Famotidine is a histamine-2 receptor antagonist, widely available over the counter at low cost,
does not interact with other medications and has
been safely used for suppression of gastric acid
production over a wide range of oral doses from
20 mg once daily to 160 mg four times daily.2 In
computer simulations, famotidine was identified
as a potential inhibitor of the 3-chymotrypsin-like
protease,3 and this and other potential mechanisms
of action for famotidine in COVID-19 are an area
of current research. In a propensity score matched
retrospective cohort study a significantly reduced
risk for death or intubation (adjusted HR 0.43,
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95% CI 0.21 to 0.88) was identified for patients with COVID-19
who were incidentally taking famotidine before or at the point
of hospital admission.4
The incentive for the retrospective cohort study were the
unexpected positive results from a group of 10 patients who
took famotidine following onset of symptoms for COVID-19.
Here, we summarise this series of 10 patients with COVID-19
who self-medicated with famotidine as outpatients. The patient-
reported demographics, clinical course, drug tolerability and
longitudinal symptom scores are provided.

Methods

Consecutive patients were enrolled in this study after signing
written informed consent for study participation and for deidentified data being reported in a published case series. No participant
was excluded. Data were collected by two telephone interviews
and two written questionnaires. Information on patient demographics, comorbidities, COVID-19 test results, famotidine use,
drug-
related side effects, temperature measurements, oxygen
saturations and symptom scores were obtained. We collected
longitudinal severity scores on five symptoms (cough, shortness
of breath, fatigue, headaches and anosmia), based on an NIH
endorsed Protocol to research Patient Experience of COVID19, in addition to general unwellness.5 Symptom scores were
retrospectively provided by patients on an ordinal scale: 1=not
affected, 2=little affected, 3=affected and 4=severely affected.
This four-point scale was based on performance status scoring in

Table 1

patients with cancer who are systemically affected by illness or
treatment. We adapted the first four scale points of the Eastern
Cooperative Oncology Group performance status (ECOG PS)
scale6 and provided explanatory text to the patients as part of
the symptom questionnaire. We chose only those scale points of
the ECOG PS as measures of grades of severity that are relevant
to a severity of COVID-19 illness that does not require hospitalisation. The relevant sections of the questionnaire with the
introduction to the scale and scoring system were provided to
the participants and are included in the online supplementary
methods section. Longitudinal symptom scores for the time
prior to the COVID-19 illness (baseline, B), the day before
starting famotidine (day −1), the day famotidine was started
(day 0) and days 1, 2, 7 and 14 after starting famotidine were
recorded. Longitudinal temperature recordings, pulse oximetry
and activity monitoring data were recorded when available.

Results
Patient characteristics
Ten individuals with the clinical diagnosis of COVID-19 who
self-
medicated with high dose oral famotidine were identified. Eight patients were from New York State, one from New
Jersey and one from Sweden. The characteristics of all study
participants are summarised in table 1. The study participants
were diverse with regard to known risk factors for severity of
COVID-19 illness: age, sex, ethnicity and body mass index

Patient characteristics

Patient

1

2

3

4

5

6

7

8

9

10

Age range
(years)

40s

40s

30s

60s

50s

20s

20s

70s

50s

60s

Gender

F

M

M

F

M

F

F

M

M

M

Ethnicity

White

Hispanic

Asian

Black

White

Hispanic

Black and
Hispanic

White

South Asian

White

Height (cm)

163

152

182

163

173

157

175

188

173

191

Weight (kg)

59

100

82

100

79

59

127

96

77

136

BMI

22

43

25

38

27

24

41

27

26

37

Smoking History N

Y

N

Ex

Ex

N

N

N

Ex

Ex

Comorbidities

Epilepsy

N

N

HTN

HTN and
hyperlipidaemia

N

N

Chronic pancreatitis
and MI

Hyperlipidaemia

N

Regular
medication

Kepra

 

 

Nifedipine,
telmisartan and
HCT.

Lisinopril and
atorvastatin.

 

 

Metoprolol, ASA and ASA and
rosuvastatin.
rosuvastatin.

 

Tylenol

Once

 

1–2×/day 1 mg  

 

 

For 5 days

 

 

 

Test method

Nasal swab
PCR

Nasal swab
PCR

Nasal swab
PCR

AB test*

Nasal swab
PCR

Nasal swab
PCR

Nasal swab
PCR

Clinical diagnosis

Nasal swab
PCR

AB test*

Test date

04/03

03/27

03/30

05/01

04/10

04/20

04/20

 04/30

04/16

05/04

Start symptoms

03/24

03/25

03/21

04/03

04/10

04/12

04/15

03/10

04/14

03/23

Start Fam.

03/28

04/02

03/30

04/13

04/16

04/21

04/21

04/05

04/16

03/30

Stop Fam.

04/07

04/12

04/05

04/24

04/23

05/08

05/02

04/09

05/06

04/03

Fam. dose

80 mg three
times a day

80 mg three
times a day

80 mg three
times a day

50 mg three times 80 mg three times
a day
a day

80 mg three
times a day

80 mg three
times a day

60 mg two times
per day

60 mg two times
per day

20 mg three
times a day

Symptoms†

 

 

 

 

 

 

 

 

 

 

 Body ache

 

Y

Y

Y

 

 

Y

 

Y

 

 Chest
tightness

 

 

 

Y

Y

 

 

Y

 

 

 Others

 

Sweating.

Chills and
hives.

 Body spasms.

Sore throat.

Congested
nose and GI
symptoms.

Sinusitis/
congested
nose.

Slow motion
performance.

GI symptoms and
dehydration.

Influenza
symptoms.

AEs

 

 

 

 

 

Racing
heartbeat and
dizziness.

Dizziness,
dry skin and
insomnia.

 

(GI symptoms and
forgetfulness)

 

In order to comply with journal guidelines for anonymisation ages are provided as age ranges.
*Pt 4: test by Mount Sinai Health Systems, USA, titre: 2880; pt 10: test by Mount Sinai Health Systems, USA, titre: 2880.
†In addition to those symptoms scored in the questionnaire; dates displayed as month/day.
AB, antibody; AEs, adverse events, in parenthesis if only possibly related to famotidine; BMI, body mass index; F, female; Fam., famotidine; HCT, hydrochlorothiazide; HTN, hypertension; M, male; N, no; Y, yes.
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reported within 24 hours of starting famotidine and symptoms
continued to improve and nearly normalised to preillness levels
at 14 days after first famotidine use (figure 3). The improvement
of symptoms was across all categories, but airway-related symptoms such as cough and shortness of breath were reported to
improve more rapidly than systemic symptoms such as fatigue
(figure 2).

Individual case summaries

Figure 1 Symptomatic days before famotidine start. The durations of
symptoms prior to starting famotidine are displayed in ascending order
for individual patients.
(BMI).7 Seven patients had positive PCR-based diagnoses from
nasal swabs for SARS-CoV-2, two patients had positive serological tests for antibodies directed against the virus and one
patient had a clinical diagnosis without molecular confirmation
(table 1). All started taking famotidine while feeling unwell with
COVID-19. The most commonly used dose was 80 mg oral
famotidine three times daily (n=6), and the dose ranged from
20 mg three times daily to 80 mg three times daily. Median duration of famotidine self-administration was 11 days (range 5–21
days). The time period between onset of symptoms and starting
treatment differed widely between patients, ranging from 2 days
to 26 days (figure 1).

Patient-reported toxicity

Seven patients did not experience any adverse events. One
patient reported grade 1 dizziness and very occasional perceptions of a racing heartbeat. Another patient experienced grade 1
dizziness, dry skin and insomnia. A third patient reported grade
1 gastroenterological symptoms and temporary forgetfulness
(table 1). Other than forgetfulness, all of these side effects are
listed in the prescription information for famotidine,2 and all
side effects resolved on discontinuation of famotidine.

Patient-reported outcomes and symptoms

No hospitalisations were reported by any of the participants,
and at the point of submission of this manuscript, patients
reported feeling fully recovered apart from persistent anosmia
in two cases. All patients were asymptomatic prior to developing
COVID-19. They all were affected by a wide range of symptoms
when they were feeling worst, and this was comparable with
how they felt on the day prior to starting famotidine. On starting
famotidine, all patients reported improvement of symptoms
within 24–48 hours (case synopses and figure 2). When we analysed the changes of the normalised total symptom score across
all patients, we found no significant difference for the day before
starting famotidine compared with the day of starting famotidine, but a significant improvement in the symptom score was
Janowitz T, et al. Gut 2020;0:1–6. doi:10.1136/gutjnl-2020-321852

Patient 1 is a white woman in her 40s with a medical history of
epilepsy for which she takes levetiracetam 1 g daily. She took
famotidine 80 mg three times daily for 11 days starting 4 days
after first experiencing symptoms of COVID-19. She reported
feeling very unwell at this time point. Within 1 day of the first dose
of famotidine, she noticed marked improvement of her shortness
of breath. This improvement was matched by an increase in her
home-
monitored pulse oximetry measured oxygen saturation
levels from 91%–95% to 97%–98% (figure 4A). She was febrile
with a temperature of 37.8°C prior to starting famotidine and
afebrile on day 7 of taking famotidine.
Patient 2 is a Hispanic man in his 40s without pre-existing
conditions. He took famotidine 80 mg three times daily for 11
days starting 8 days after first experiencing symptoms of COVID19. He reported improvement of symptoms within 2 days of
treatment. He was febrile with a temperature of 38.3°C prior to
starting famotidine and afebrile on day 5 of taking famotidine.
Patient 3 is an Asian man in his 30s without pre-existing
conditions. He took famotidine 80 mg three times daily for
7 days starting 9 days after first experiencing symptoms of
COVID-19. He experienced severe shortness of breath prior
to starting famotidine, and his dyspnoea and other symptoms
improved by day 7. His home monitored oxygen saturation
levels improved from 89% on day 2 of treatment to 96% on
day 5 of treatment (figure 4A). He was febrile with a temperature of 38.9°C prior to starting famotidine and afebrile on day
5 of taking famotidine. He intermittently took paracetamol for
fever during illness.
Patient 4 is a black woman in her 60s with a BMI of 38,
positive smoking history and hypertension controlled by triple
therapy. She took famotidine 50 mg three times daily for 12 days
starting 10 days after first experiencing symptoms of COVID19. She noticed improvement in muscle aches and chest tightness
in addition to those recorded in figure 2.
Patient 5 is a white man in his 50s iswith hypertension and
hyperlipidaemia, both treated with medications, and positive smoking history. He took famotidine 80 mg three times
daily for 8 days starting 6 days after first experiencing symptoms of COVID-19. He described ongoing increase of fatigue
for another 7 days after starting famotidine; the only patient
to describe worsening of any symptoms during this treatment
period. However, he noticed improvement in respiratory symptoms within 2 days of starting famotidine.
Patient 6 is a Hispanic woman in her 20s with no pre-existing
conditions. She took famotidine 80 mg three times daily starting
9 days after first experiencing symptoms of COVID-19. She felt
markedly better within 2 days of treatment but had mild dizziness and accelerated heart beats intermittently while taking
famotidine.
Patient 7 is a black and Hispanic woman in her 20s with a
BMI of 41 with no pre-existing conditions. She took famotidine 80 mg three times daily for 12 days starting 6 days after
first experiencing symptoms of COVID-19. Within 1 week of
treatment, she reported relief of most symptoms. She reported
3
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Figure 2 Patient level symptom scores. The longitudinal data for all reported symptoms are shown for individual patients. The mean is indicated as
a dashed black line. The baseline scores are indicated adjacent to the y-axis. All patients reported baseline symptoms at 1. Colour-coded lines and dots
for respective symptoms are ordered alphabetically and are slightly offset to avoid overlap. Day 0 indicates the day at which patients took the first
dose of famotidine. Severity score: 1=not affected, 2=little affected, 3=affected, 4=severely affected. B, baseline; Pt, patient.
grade 1 dizziness, insomnia and dry skin concurrent with taking
famotidine.
Patient 8 is a white man in his 70s with history of myocardial infarction, surgery for a benign pancreatic tumour, chronic
pancreatitis and chronic back pain. His diagnosis is based on
clinical symptoms and signs and being from a high prevalence
location, with all family members being clinically affected by
COVID-19. He took Famotidine 60 mg two times daily for 5 days
starting 26 days after first experiencing symptoms of COVID19. He reported a rapid improvement and being asymptomatic
within 3 days of treatment. He routinely monitors his activity
using an Oura Ring device and was able to provide readings
4

on walking equivalence, calorie usage and activity score for the
weeks before and after starting famotidine, which all showed
marked improvements (figure 4B–D).
Patient 9 is a South Asian ex-smoker man in his 50s with
history of hyperlipidaemia controlled by rosuvastatin. He took
famotidine 60 mg two times daily for 21 days starting 2 days
after first experiencing symptoms of COVID-19. He described
improvement in his symptoms within 2 days of starting famotidine. He reported possible famotidine associated mild forgetfulness and gastroenterological symptoms that started while
he was on famotidine but resolved before he stopped the
medication.
Janowitz T, et al. Gut 2020;0:1–6. doi:10.1136/gutjnl-2020-321852
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ns

Standardized symptom score

1.0

a universal improvement in symptoms within the first week of
taking famotidine.

*
*

0.8

Discussion

0.6

***

0.4

****

0.2

0.0
B

-1 0

1

2

7

14

Time [Days since starting Famotidine]

Figure 3 Normalised symptom scores of all patients. The mean
longitudinal normalised symptom score for all patients is shown. The
SE of the mean is indicated. Statistical comparisons by two-sided t-test
in comparison with day 0, the day of starting famotidine. *P<0.05;
***p<0.001; ****p<0.0001. NS, not significant.
Patient 10 is a white former smoker man in his 60s with a
BMI of 37.5 without known pre-existing conditions. He took
famotidine 20 mg three times daily for 5 days starting 7 days
after first experiencing symptoms of COVID-19. He reported

This case series provides patient-
reported outcome measures
for 10 consecutively enrolled non-
hospitalised patients with
COVID-19. They all noticed improvements in their condition
in correlation with famotidine use at doses ranging from 60 mg
to 240 mg daily. Based on published pharmacokinetic data for
famotidine,8 9 we estimate that these treatment regimens would
have resulted in peak plasma concentrations of approximately
0.5–2 µM and average plasma concentrations of approximately
0.15–0.7 µM famotidine, assuming normal kidney function.
In concordance with the clinical evidence and consensus that
famotidine is safe across a wide range of doses and frequencies,
famotidine was very well tolerated by all patients. Given that
famotidine has only minimal inhibitory effect on the hepatic
cytochrome p450 system and low risk of clinically significant
alterations in oxidative drug metabolism,10 11 it may be a safe
drug for testing in a trial or clinical setting where patients self-
administer the medication.
A pertinent aspect of this work is the exploration and application of graded symptom scores and patient-reported outcome
measures in tracking COVID-19 in the non-hospitalised setting
using a four-point ordinal scale. Using these symptom scores,
we were able to determine that all patients noticed a rapid

Figure 4 Patient-level pulse oximetry and activity results. (A) The pulse oximetry data from two patients are displayed. (B–D) The device software
provided display of weekly data relating to three metrices recorded using an Oura Ring are displayed for patient 8. The mean for each metric over the
displayed period is indicated by a dashed line. Day 0 and week 0 represent the day and week of starting famotidine, respectively. Pt, patient.
Janowitz T, et al. Gut 2020;0:1–6. doi:10.1136/gutjnl-2020-321852
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improvement in their condition within 24–48 hours of starting
famotidine. Our quantitative approach to follow symptom
severity may be a useful tool, in particular for outpatient studies,
but requires validation. In addition, for all patients who were
able to provide data, temperature readings, oxygen saturations
and activity improved in correlation with taking famotidine.
These findings suggest that famotidine may affect the course
of COVID-19 but must be considered in the context of several
limitations. Placebo effect, enrolment bias and recall bias12 for
symptoms may affect our findings as is the case for the outcome
measures of any non-blinded, non-controlled study, despite us
attempting to minimise bias by asking non-leading questions. An
improvement of symptoms was noticed within 48 hours by all
individuals in this study, despite the symptomatic period prior to
taking famotidine varying widely. There remains the possibility,
however, that these changes may reflect treatment independent
convalescence, as the natural course of COVID-19 in patients
who do not require hospital admission is not well characterised.
Our case series suggests, but does not establish, a benefit from
famotidine treatment in outpatients with COVID-19. Future
work will investigate potential mechanisms of action and clinical
relevance of famotidine. Mechanistically, famotidine could have
a viral target, for example, one of the viral proteases, or a host
target, resulting, for example, in modulation of the immunological response to the virus. Clinically, we unreservedly share the
opinion that well designed and informative studies of efficacy
are required to evaluate candidate medications for COVID-19
as for other diseases.13 A randomised phase III trial testing the
efficacy of high dose intravenous famotidine three times daily
in addition to hydroxychloroquine in hospitalised patients with
COVID-19 has recently commenced (NCT04370262). An
outpatient study of oral famotidine that investigates efficacy for
symptom control, viral burden and disease outcome and assesses
effects of medication use on long term immunity should be
considered to establish if famotidine may be of use in controlling
COVID-19 in individual patients while also reducing the risk of
SARS-CoV-2 transmission.

Conclusions

The results presented in this case series suggest that high-dose
oral famotidine is well tolerated and associated with improved
self-
reported outcomes in non-
hospitalised patients with
COVID-19.
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